-
1
-
-
84858604270
-
Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate
-
Ward PS and Thompson CB (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21(3), 297-308.
-
(2012)
Cancer Cell
, vol.21
, Issue.3
, pp. 297-308
-
-
Ward, P.S.1
Thompson, C.B.2
-
2
-
-
60849115270
-
IDH1 and IDH2 mutations in gliomas
-
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8), 765-773.
-
(2009)
N Engl J Med
, vol.360
, Issue.8
, pp. 765-773
-
-
Yan, H.1
Parsons, D.W.2
Jin, G.3
McLendon, R.4
Rasheed, B.A.5
Yuan, W.6
Kos, I.7
Batinic-Haberle, I.8
Jones, S.9
Riggins, G.J.10
-
3
-
-
18544365990
-
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
-
Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al. (2002). Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30(4), 406-410.
-
(2002)
Nat Genet
, vol.30
, Issue.4
, pp. 406-410
-
-
Tomlinson, I.P.1
Alam, N.A.2
Rowan, A.J.3
Barclay, E.4
Jaeger, E.E.5
Kelsell, D.6
Leigh, I.7
Gorman, P.8
Lamlum, H.9
Rahman, S.10
-
4
-
-
80052258995
-
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
-
Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43(9), 869-874.
-
(2011)
Nat Genet
, vol.43
, Issue.9
, pp. 869-874
-
-
Locasale, J.W.1
Grassian, A.R.2
Melman, T.3
Lyssiotis, C.A.4
Mattaini, K.R.5
Bass, A.J.6
Heffron, G.7
Metallo, C.M.8
Muranen, T.9
Sharfi, H.10
-
5
-
-
84860321700
-
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
-
Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3), 656-670.
-
(2012)
Cell
, vol.149
, Issue.3
, pp. 656-670
-
-
Ying, H.1
Kimmelman, A.C.2
Lyssiotis, C.A.3
Hua, S.4
Chu, G.C.5
Fletcher-Sananikone, E.6
Locasale, J.W.7
Son, J.8
Zhang, H.9
Coloff, J.L.10
-
6
-
-
84859215796
-
Systemic elevation of PTEN induces a tumor-suppressive metabolic state
-
Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VCJ, Anastasiou D, Ito K, Sasaki AT, Rameh L, et al. (2012). Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149(1), 49-62.
-
(2012)
Cell
, vol.149
, Issue.1
, pp. 49-62
-
-
Garcia-Cao, I.1
Song, M.S.2
Hobbs, R.M.3
Laurent, G.4
Giorgi, C.5
de Boer, V.C.J.6
Anastasiou, D.7
Ito, K.8
Sasaki, A.T.9
Rameh, L.10
-
7
-
-
79957955614
-
NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism
-
Burgos ES (2011). NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr Med Chem 18(13), 1947-1961.
-
(2011)
Curr Med Chem
, vol.18
, Issue.13
, pp. 1947-1961
-
-
Burgos, E.S.1
-
8
-
-
37549068090
-
NAD+/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences
-
Ying W (2008). NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10(2), 179-206.
-
(2008)
Antioxid Redox Signal
, vol.10
, Issue.2
, pp. 179-206
-
-
Ying, W.1
-
9
-
-
50949120914
-
Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition
-
Bogan KL and Brenner C (2008). Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 28, 115-130.
-
(2008)
Annu Rev Nutr
, vol.28
, pp. 115-130
-
-
Bogan, K.L.1
Brenner, C.2
-
10
-
-
0038614824
-
Enzymatic synthesis of nicotinamide mononucleotide
-
Preiss J and Handler P (1957). Enzymatic synthesis of nicotinamide mononucleotide. J Biol Chem 225(2), 759-770.
-
(1957)
J Biol Chem
, vol.225
, Issue.2
, pp. 759-770
-
-
Preiss, J.1
Handler, P.2
-
11
-
-
70449212074
-
Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates
-
Preiss J and Handler P (1958). Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J Biol Chem 233(2), 488-492.
-
(1958)
J Biol Chem
, vol.233
, Issue.2
, pp. 488-492
-
-
Preiss, J.1
Handler, P.2
-
12
-
-
70350538957
-
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: Strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors
-
Watson M, Roulston A, Bélec L, Billot X, Marcellus R, Bédard D, Bernier C, Branchaud S, Chan H, Dairi K, et al. (2009). The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 29(21), 5872-5888.
-
(2009)
Mol Cell Biol
, vol.29
, Issue.21
, pp. 5872-5888
-
-
Watson, M.1
Roulston, A.2
Bélec, L.3
Billot, X.4
Marcellus, R.5
Bédard, D.6
Bernier, C.7
Branchaud, S.8
Chan, H.9
Dairi, K.10
-
13
-
-
38149105811
-
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
-
Holen K, Saltz LB, Hollywood E, Burk K, and Hanauske AR (2008). The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26(1), 45-51.
-
(2008)
Invest New Drugs
, vol.26
, Issue.1
, pp. 45-51
-
-
Holen, K.1
Saltz, L.B.2
Hollywood, E.3
Burk, K.4
Hanauske, A.R.5
-
14
-
-
0036716986
-
A phase I study of CHS 828 in patients with solid tumor malignancy
-
Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lonnebo A, and Ahlgren J (2002). A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 8(9), 2843-2850.
-
(2002)
Clin Cancer Res
, vol.8
, Issue.9
, pp. 2843-2850
-
-
Hovstadius, P.1
Larsson, R.2
Jonsson, E.3
Skov, T.4
Kissmeyer, A.M.5
Krasilnikoff, K.6
Bergh, J.7
Karlsson, M.O.8
Lonnebo, A.9
Ahlgren, J.10
-
15
-
-
14844291424
-
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study
-
Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, and Twelves C (2005). Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41(5), 702-707.
-
(2005)
Eur J Cancer
, vol.41
, Issue.5
, pp. 702-707
-
-
Ravaud, A.1
Cerny, T.2
Terret, C.3
Wanders, J.4
Bui, B.N.5
Hess, D.6
Droz, J.P.7
Fumoleau, P.8
Twelves, C.9
-
16
-
-
77951887249
-
Safety and efficacy of NAD depleting cancer drugs: Results of a phase I clinical trial of CHS 828 and overview of published data
-
von Heideman A, Berglund A, Larsson R, and Nygren P (2010). Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 65(6), 1165-1172.
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, Issue.6
, pp. 1165-1172
-
-
von Heideman, A.1
Berglund, A.2
Larsson, R.3
Nygren, P.4
-
17
-
-
0014960271
-
Uptake and metabolism of nicotinic acid by human blood platelets. Effects of structure analogs and metabolic inhibitors
-
Gaut ZN and Solomon HM (1970). Uptake and metabolism of nicotinic acid by human blood platelets. Effects of structure analogs and metabolic inhibitors. Biochim Biophys Acta 201(2), 316-322.
-
(1970)
Biochim Biophys Acta
, vol.201
, Issue.2
, pp. 316-322
-
-
Gaut, Z.N.1
Solomon, H.M.2
-
18
-
-
77953408297
-
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor
-
Olesen UH, Thougaard AV, Jensen PB, and Sehested M (2010). A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 9(6), 1609-1617.
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.6
, pp. 1609-1617
-
-
Olesen, U.H.1
Thougaard, A.V.2
Jensen, P.B.3
Sehested, M.4
-
19
-
-
84873981203
-
A phase I trial of GMX1777: An inhibitor of nicotinamide phosphoribosyl transferase (NAMPT), given as a 24 hour infusion
-
Pishvaian MJ, Marshall JL, Hwang JH, Malik S, He AR, Deeken JF, Kelso CB, Cotarla I, and Berger MS (2009). A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPT), given as a 24 hour infusion. J Clin Oncol 27(15S), Suppl Abstract 3581.
-
(2009)
J Clin Oncol
, pp. 3581
-
-
Pishvaian, M.J.1
Marshall, J.L.2
Hwang, J.H.3
Malik, S.4
He, A.R.5
Deeken, J.F.6
Kelso, C.B.7
Cotarla, I.8
Berger, M.S.9
-
20
-
-
66449111040
-
High-throughput generation of tagged stable cell lines for proteomic analysis
-
Torres JZ, Miller JJ, and Jackson PK (2009). High-throughput generation of tagged stable cell lines for proteomic analysis. Proteomics 9(10), 2888-2891.
-
(2009)
Proteomics
, vol.9
, Issue.10
, pp. 2888-2891
-
-
Torres, J.Z.1
Miller, J.J.2
Jackson, P.K.3
-
21
-
-
79952741730
-
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
-
Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, and Yan H (2011). Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108(8), 3270-3275.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, Issue.8
, pp. 3270-3275
-
-
Reitman, Z.J.1
Jin, G.2
Karoly, E.D.3
Spasojevic, I.4
Yang, J.5
Kinzler, K.W.6
He, Y.7
Bigner, D.D.8
Vogelstein, B.9
Yan, H.10
-
22
-
-
29344465338
-
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
-
Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, et al. (2005). Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11(24), 8686-8698.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.24
, pp. 8686-8698
-
-
Yauch, R.L.1
Januario, T.2
Eberhard, D.A.3
Cavet, G.4
Zhu, W.5
Fu, L.6
Pham, T.Q.7
Soriano, R.8
Stinson, J.9
Seshagiri, S.10
-
23
-
-
77951820899
-
Fast and SNP-tolerant detection of complex variants and splicing in short reads
-
Wu TD and Nacu S (2010). Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26(7), 873-881.
-
(2010)
Bioinformatics
, vol.26
, Issue.7
, pp. 873-881
-
-
Wu, T.D.1
Nacu, S.2
-
24
-
-
77958471357
-
Differential expression analysis for sequence count data
-
Anders S and Huber W (2010). Differential expression analysis for sequence count data. Genome Biol 11(10), R106.
-
(2010)
Genome Biol
, vol.11
, Issue.10
-
-
Anders, S.1
Huber, W.2
-
25
-
-
84873291018
-
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: Metabolic basis and potential clinical implications
-
Tan B, Young DA, Lu Z-H, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo M-S, et al. (2013). Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem 288(5), 3500-3511.
-
(2013)
J Biol Chem
, vol.288
, Issue.5
, pp. 3500-3511
-
-
Tan, B.1
Young, D.A.2
Lu, Z.-H.3
Wang, T.4
Meier, T.I.5
Shepard, R.L.6
Roth, K.7
Zhai, Y.8
Huss, K.9
Kuo, M.-S.10
-
26
-
-
84863090408
-
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells
-
Bowlby SC, Thomas MJ, D'Agostino RB Jr, and Kridel SJ (2012). Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS One 7(6), e40195.
-
(2012)
PLoS One
, vol.7
, Issue.6
-
-
Bowlby, S.C.1
Thomas, M.J.2
D'Agostino Jr., R.B.3
Kridel, S.J.4
-
27
-
-
44449171041
-
Characterization of NAD uptake in mammalian cells
-
Billington RA, Travelli C, Ercolano E, Galli U, Roman CB, Grolla AA, Canonico PL, Condorelli F, and Genazzani AA (2008). Characterization of NAD uptake in mammalian cells. J Biol Chem 283(10), 6367-6374.
-
(2008)
J Biol Chem
, vol.283
, Issue.10
, pp. 6367-6374
-
-
Billington, R.A.1
Travelli, C.2
Ercolano, E.3
Galli, U.4
Roman, C.B.5
Grolla, A.A.6
Canonico, P.L.7
Condorelli, F.8
Genazzani, A.A.9
-
28
-
-
84868588684
-
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition
-
Cea M, Cagnetta A, Fulciniti M, Tai Y-T, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, et al. (2012). Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 120(17), 3519-3529.
-
(2012)
Blood
, vol.120
, Issue.17
, pp. 3519-3529
-
-
Cea, M.1
Cagnetta, A.2
Fulciniti, M.3
Tai, Y.-T.4
Hideshima, T.5
Chauhan, D.6
Roccaro, A.7
Sacco, A.8
Calimeri, T.9
Cottini, F.10
-
29
-
-
67650318141
-
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777
-
Beauparlant P, Bédard D, Bernier C, Chan H, Gilbert K, Goulet D, Gratton MO, Lavoie M, Roulston A, Turcotte E, et al. (2009). Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 20(5), 346-354.
-
(2009)
Anticancer Drugs
, vol.20
, Issue.5
, pp. 346-354
-
-
Beauparlant, P.1
Bédard, D.2
Bernier, C.3
Chan, H.4
Gilbert, K.5
Goulet, D.6
Gratton, M.O.7
Lavoie, M.8
Roulston, A.9
Turcotte, E.10
-
30
-
-
0242526050
-
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis
-
Hasmann M and Schemainda I (2003). FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63(21), 7436-7442.
-
(2003)
Cancer Res
, vol.63
, Issue.21
, pp. 7436-7442
-
-
Hasmann, M.1
Schemainda, I.2
-
31
-
-
79954878322
-
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas
-
Olesen UH, Hastrup N, and Sehested M (2011). Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS 119(4-5), 296-303.
-
(2011)
APMIS
, vol.119
, Issue.4-5
, pp. 296-303
-
-
Olesen, U.H.1
Hastrup, N.2
Sehested, M.3
|